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Purpose: The precise etiology of autoimmune hepatitis (AIH) remains unknown, although a number of genetic loci
have been implicated in the susceptibility of type 1 AIH. The purpose of this study was to test for association of
these loci with type 1 AIH in New Zealand Caucasians.
Methods: 77 AIH patients and 485 healthy controls were genotyped for the SNPs rs2187668 (HLA-DRB*03:01),
rs660895 (HLA-DRB*04:01), rs3749971 (HLA-A1-B8-DR3), rs231775 (CLTLA4), rs1800629 (TNF), and rs1800682 (FAS) using
predesigned TaqMan SNP genotyping assays. Chi square analysis was used to test for association of allele and
genotype with overall AIH, and with severe fibrosis and ALT levels at 6 months.
Results: Significant risk of AIH was conferred by the minor alleles of rs2187668 (OR = 2.45, 95% CI 1.65-3.61, p <
0.0001), rs3749971 (OR = 1.89, 95% CI 1.21-2.94, p = 0.004) and rs1800629 (OR = 2.06, 95% CI 1.41-3.01, p = 0.0001).
Multivariate analysis showed that rs2187668 was independently associated with type 1 AIH susceptibility (OR = 2.40,
95% CI 1.46-3.93, p = 0.001). The C allele of FAS SNP rs1800682 was associated with increased risk of severe fibrosis
at diagnosis (OR = 2.03, 95% CI 1.05-3.93, p = 0.035) and with incomplete normalization of ALT levels at 6 months
post-diagnosis (OR = 3.94, 95% CI 1.62-9.54, p = 0.0015).
Conclusions: This is the first population-based study to investigate genetic risk loci for type 1 AIH in New Zealand
Caucasians. We report significant independent association of HLA-DRB1*03:01 with overall susceptibility to type 1
AIH, as well as FAS with a more aggressive disease phenotype.
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Autoimmune hepatitis (AIH) is a chronic progressive in-
flammatory liver disease of unknown etiology. It has a pre-
sumed autoimmune basis to its pathogenesis that is likely
to involve a complex interaction of genetic and environ-
mental factors (Czaja et al. 2010). Identification of these
factors can potentially provide novel targets for treatment,
diagnosis and prevention. AIH can be classified into two
types according to circulating auto antibodies present in
the patients’ sera. Type 1 AIH is characterized by the pres-
ence of anti-nuclear antibodies (ANA) and/or anti smooth* Correspondence: rebecca.roberts@otago.ac.nz
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in any medium, provided the original work is pmuscle antibodies (SMA), whereas type 2 AIH is defined
by the presence of anti-liver-kidney microsome antibodies
(LKM1) (Czaja et al. 1995).
Type 1 AIH constitutes the vast majority of the disease
in Caucasian populations. Genetic predisposition in type
1 AIH has been linked especially to the human leukocyte
antigen (HLA) class II haplotype HLA-A1-B8, and the
alleles HLA-DRB1*03:01 and HLA-DRB1*04:01 in North
America and Europe (Doherty et al. 1994; Strettell et al.
1997). However, distinct differences in the pattern of as-
sociation between genetic susceptibility and type 1 AIH
are seen in populations from various geographical re-
gions. For example, type 1 AIH is associated with HLA-
DRB1*04:05 in Japan and Argentina (Seki et al. 1992;
Pando et al. 1999), with HLA-DRB1*13:01 in Brazil andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Mdel et al. 2007) and with HLA-DRB1*04:04 in Mexico
(Vazquez-Garcia et al. 1998). Polymorphisms in genes
outside the HLA locus have also been associated with
type 1 AIH. An A to G base-exchange polymorphism in
exon 1 of the cytotoxic T-lymphocyte antigen 4
(CLTLA4) is associated with increased incidence of AIH
in white North American and northern European pa-
tients (Agarwal et al. 2000; Djilali-Saiah et al. 2001), but
not in South American (Bittencourt et al. 2003) and
Japanese patients (Umemura et al. 2008). In young white
AIH patients, the tumor necrosis factor (TNF) poly-
morphism -308G > A is associated with a poorer re-
sponse to corticosteroid therapy. A Fas gene promoter
polymorphism was found to influence susceptibility to
AIH and its progression (Hiraide et al. 2005; Agarwal
et al. 2007), leading to a more aggressive disease with an
early development of cirrhosis (Hiraide et al. 2005).
Polymorphisms in the vitamin D receptor gene have also
been associated with AIH in German and Chinese pa-
tients (Vogel et al. 2002; Fan et al. 2005).
In New Zealand, only 2% of the AIH cases have a posi-
tive LKM1 antibody, indicating that type 1 AIH is the
predominant disease in this population (Ngu et al.
2010). However, genetic loci previously shown to alter
susceptibility to type 1 AIH have yet to be investigated
in the New Zealand population. Our study had two aims.
The first aim was to test for the association of six candi-
date risk loci (HLA-A1-B8, HLA-DRB1*03:01, HLA-DRB1
*04:01, CTLA4, FAS, and TNF) in a population-based AIH
New Zealand Caucasian cohort. The second aim was to
examine whether these loci are associated with specific
AIH phenotypes such as severe liver fibrosis stage at diag-
nosis and response to initial immunosuppression.
Patients and methods
Study population
Cases were New Zealand Caucasian with type 1 AIH
who resided in the geographically defined region of
Canterbury between 1st July 2011 and 30th June 2012.
The list of AIH patients in Canterbury was generated
from the established population-based AIH database that
was set up in 2006 which has recorded information on
the demography, biochemistry, serology, histology, radi-
ology, and treatment of these patients. The methods used
to identify these patients were described in detail in our
earlier studies (Ngu, Bechly et al. 2010; Ngu et al. 2012).
In brief, every new diagnosis of AIH in Canterbury was
recruited prospectively since 2007. Cases diagnosed before
2006 were identified retrospectively by detailed searching
of all private and public gastroenterology records in
Canterbury. Cases were included into the database if they
had definite or probable AIH as determined using the re-
vised original scoring system (Alvarez et al. 1999). Casesthat had a positive anti-LKM antibody (type 2 AIH) were
excluded from this study. Stages of fibrosis were evalu-
ated using the Metavir scoring system, and severe liver
fibrosis was defined as Metavir stage 3 and 4. Response
to initial immunosuppression was defined as normal
ALT (<30 U/L) at 6 months from diagnosis, as incom-
plete normalization of ALT had been identified as an in-
dependent predictor of poor outcome in our earlier
study (Ngu et al. 2013). Controls were healthy New
Zealand Caucasians who were aged over 17 years of age
at the time of the study and who had no personal or
family history of autoimmune or inflammatory disease
(Simkins et al. 2005). All study participants gave their in-
formed written consent and ethical approval for this
study was obtained from the Upper South A Regional
Ethics Committee of New Zealand (approval number
URA/10/07/055).
Genotyping of susceptibility loci
Genomic DNA was obtained from peripheral blood
using sodium chloride extraction (Miller et al. 1988) and
re-suspended in Tris-EDTA buffer (pH 8.0) and stored
at −20°C until analysis. Study participants were geno-
typed for all six loci using predesigned TaqMan SNP
genotyping assays following the manufacturer’s instruc-
tions (Applied Biosystems, Foster City, CA, USA).
Briefly, assays were performed in a total reaction volume
of 5μl containing 2.5μl of 2× TaqMan® Universal Master
Mix (Roche Molecular Systems Inc, Branchburg, NJ,
USA), 0.25 μl of 20× working mix of SNP genotyping
assay and 12 ng of genomic DNA. The PCR was
performed on an Roche LightCycler 480 Real-time PCR
system, with an activation step of 10 min at 95°C, fol-
lowing by 40 cycles of denaturation (15 sec at 92°C) and
annealing/extension (1 min at 60°C). Genotypes were
assigned using the end-point genotyping analysis soft-
ware. CTLA4 rs231775, FAS rs1800682, and TNF
rs1800629 genotyped using the predesigned TaqMan
SNP genotyping assays C_2415786_20, C_9578811_10,
and C_7514879_10, respectively. HLA-A1-B8, HLA-DR1
*03:01, and HLA-DR1*04:01 were genotyped indirectly
using the tagging SNPs rs3749971 (C_25983472_20)
(Santos et al. 2008), rs2187668 (C_58662585_10)
(Stanescu et al. 2011), rs660895 (C_26546458_30)
(Ahmed et al. 2012). The web-based analysis programme
SHEsis (http://analysis2.bio-x.cn/myAnalysis.php) (Shi
et al. 2005) was used to check for deviations in Hardy-
Weinberg Equilibrium (HWE).
Statistical analysis
Tests for association of allele and genotype with overall
AIH, and comparisons between groups with and without
severe fibrosis at AIH diagnosis, and between those who
did or did not normalize ALT within the first six months
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odd ratios (OR) with 95% confidence intervals (CI). As-
sociations were considered significant if p < 0.05.
Bonferroni corrections of α = 0.05/6 (p < 0.008) and
α = 0.05/12 (p < 0.004) were used to adjust for multiple
testing for associations with overall susceptibility and
clinical phenotypes, respectively. Multivariate analysis,
using a conditional logistic regression was used to deter-
mine the independent association of significant risk al-
leles identified from the univariate analyses.
Results
Characteristics of the study cohorts
Of the 85 type 1 AIH patients that fulfilled the study in-
clusion criteria, 77 cases (91% of the eligible cases)
agreed to participate in this study. The basic demo-
graphics of these cases are shown in Table 1. All cases
and controls (n = 455) were successfully genotyped for
the six SNPs. No deviations from HWE were observed
for any of these SNPs in either cases or controls.
Association of HLA, CTLA4, FAS and TNF with type 1 AIH
susceptibility
Chi-square analysis identified significant association of
rs2187668 (HLA-DRB1*03:01), rs3749971 (HLA-A1-B8-
DR3), and rs1800629 (TNF) with overall susceptibility to
type 1 AIH (Table 2). No evidence of association of
rs660895 (HLA-DRB*04:01), rs231775 (CLTLA4), or
rs1800682 (FAS) with overall AIH susceptibility was
detected. Minor allele A of HLA-DRB1*03:01 SNP
rs2187668 conferred nearly 2.5 times increased risk of
susceptibility to type 1 AIH (OR = 2.45, 95% CI 1.65-
3.61, p < 0.0001). Minor alleles of both rs3749971 (HLA-
A1-B8-DR3) and rs1800629 (TNF) were associated with
2 times increased risk of type 1 AIH with OR of 1.89
(95% CI 1.21-2.94, p = 0.004) and 2.06 (95% CI 1.41-3.01,
p = 0.0001) respectively. All three associations remained
significant after adjustment for multiple testing.Table 1 Baseline characteristics of type 1 AIH patients at
diagnosis
Baseline features




Mean age (years) 45
Median age (years, range) 50 (12–74)
ALT U/L (mean, 95% CI) 571 (428–714)
Bilirubin umol/L (mean, 95% CI) 95 (62–128)
Albumin g/L (mean, 95% CI) 37 (36–38)
No. cases with histological stage≥Metavir 3 45 (58%)Multivariate logistic regression was performed using
both forward and backward stepwise analysis, and in-
cluding all factors significant (p < 0.05) from the univari-
ate association. This analysis showed that only
rs2187668 (HLA-DRB1*03:01) was independently associ-
ated with overall susceptibility to type 1 AIH (OR = 2.40
[95% CI 1.46-3.93], p = 0.001). SNP rs3749971 (HLA-A1-
B8-DR3) and rs1800629 (TNF) did not show independ-
ent association under this multivariate model. Further
scrutiny indicated that the presence of minor allele
rs2187668 (HLA-DRB1*03:01) was in fact significantly
associated with the presence of minor allele rs3749971
(HLA-A1-B8-DR3) and rs1800629 (TNF) (p < 0.001).
Association of HLA, CTLA4, FAS, and TNF loci with severe
liver fibrosis and normalization of ALT
We examined whether these loci are associated with
specific AIH phenotypes such as severe liver fibrosis
stage at diagnosis and normalization of ALT at 6 months
post diagnosis (Table 3). At diagnosis, 58% of the cases
had severe liver fibrosis (Metavir ≥ 3), and 68% of the
cases achieved complete normalization of ALT at
6 months post diagnosis. Within case analysis showed
that whilst the C allele of the FAS SNP rs1800682 was
significantly associated with incomplete normalization of
ALT at 6 months post-diagnosis (OR = 3.94, [95% CI
1.62-9.54], p = 0.0015), this allele also increased the risk
of severe fibrosis at diagnosis (OR = 2.03, [95% CI 1.05-
3.93], p = 0.035). The latter association did not remain
significant after Bonferroni correction. In addition, no
association of rs231775, rs2187668, rs660895, rs3749971,
or rs1800629 with severe fibrosis at diagnosis or with in-
complete normalization of ALT at 6 months post-
diagnosis was detected.
Discussion
AIH is a multi-factorial disease that is believed to de-
velop when a genetically susceptible individual is ex-
posed to an environmental factor that triggers the loss
of immune tolerance towards hepatocyte antigens. The
number and nature of the genes that play a role in AIH
development is, at present, poorly defined. To date, the
strongest genetic associations for type 1 AIH have been
observed with genes located in the major histocompati-
bility complex (MHC), although several non-MHC genes
have also been implicated in type 1 disease including
CTLA4, FAS, and TNF. Our study is the first to investi-
gate type 1 AIH susceptibility loci in New Zealand
Caucasians.
In our cohort, the most significant association was ob-
served between the HLA-DRB1*03:01 tagging SNP
rs2187668 and overall AIH susceptibility, with the minor
allele of this SNP conferring a strong risk effect. This
finding is consistent with previous reports in European
Table 2 Allele and genotype frequencies of HLA, CTLA4, FAS and TNF SNPs in New Zealand Caucasian controls and patients with type 1 AIH
SNP Phenotype Genotype frequency Minor allele frequency Unadjusted P (allele) Odd ratio (allele) [95% CI]
rs2187668 (HLA-DRB1*03:01) AA AG GG A
AIH 10(0.130) 26(0.338) 41(0.532) 46(0.299) <0.0001± 2.45 [1.65-3.61]
Controls 13(0.029) 109(0.240) 333(0.732) 135(0.148)
rs660895 (HLA-DRB1*04:01) AA AG GG G
AIH 41(0.532) 31(0.403) 5(0.065) 41(0.266) 0.10 0.72 [0.49-1.07]
Controls 288(0.633) 145(0.319) 22(0.048) 189(0.208)
rs3749971 (HLA-A1-B8-DR3) AA AG GG A
AIH 4(0.052) 23(0.299) 50(0.649) 31(0.201) 0.004± 1.89 [1.21-2.94]
Controls 4(0.009) 98(0.218) 348(0.773) 106(0.118)
rs231775 (CTLA4) AA AG GG G
AIH 33(0.429) 32(0.416) 12(0.156) 56(0.364) 0.42 1.16 [0.81-1.65]
Controls 168(0.369) 212(0.466) 75(0.165) 362(0.398)
rs1800629 (TNF) AA AG GG A
AIH 10(0.130) 29(0.377) 38(0.494) 49(0.318) 0.0001± 2.06 [1.41-3.01]
Controls 20(0.044) 128(0.281) 307(0.675) 168(0.185)
rs1800682 (FAS) CC CT TT C
AIH 19(0.247) 35(0.455) 23(0.299) 73(0.474) 0.93 1.01 [0.72-1.43]
Controls 107(0.235) 214(0.470) 134(0.295) 428(0.470)















Table 3 Association of HLA, CTLA, FAS, and TNF loci with severe fibrosis and normalisation of ALT in type 1 AIH patients






AA AG GG A
Fibrosis ≥Metavir 3 Yes 4(0.089) 16(0.356) 25(0.556) 24(0.267) 0.46 0.76 [0.38-1.55]
(at diagnosis) No 5(0.161) 10(0.323) 16(0.516) 20(0.323)
Incomplete normalization of ALT Yes 1(0.067) 6(0.400) 8(0.533) 8(0.267) 0.67 0.82 [0.34-2.01]
(at 6 months post diagnosis) No 9(0.145) 20(0.323) 33(0.532) 38(0.306)
rs660895 (HLA-DRB1*04:01) AA AG GG G
Fibrosis ≥Metavir 3 Yes 27(0.600) 15(0.333) 3(0.067) 21(0.233) 0.22 1.56 [0.76-3.22]
(at diagnosis) No 13(0.419) 16(0.516) 2(0.065) 20(0.323)
Incomplete normalization of ALT Yes 9(0.600) 4(0.267) 2(0.133) 8(0.267) 0.96 1.00 [0.40-2.46]
(at 6 months post diagnosis) No 32(0.516) 27(0.435) 3(0.048) 33(0.266)
rs3749971 (HLA-A1-B8-DR3) AA AG GG A
Fibrosis ≥Metavir 3 Yes 3(0.067) 13(0.289) 29(0.644) 19(0.211) 0.26 1.24 [0.54-2.83]
(at diagnosis) No 1(0.032) 9(0.290) 21(0.677) 11(0.177)
Incomplete normalization of ALT Yes 0(0.000) 6(0.400) 9(0.600) 6(0.200) 0.98 0.99[0.37-2.68]
(at 6 months post diagnosis) No 4(0.065) 17(0.274) 41(0.661) 25(0.202)
rs231775 (CTLA4) AA AG GG G
Fibrosis ≥Metavir 3 Yes 20(0.444) 15(0.333) 10(0.222) 35(0.389) 0.29 0.69 [0.35-1.38]
(at diagnosis) No 13(0.419) 17(0.548) 1(0.032) 19(0.306)
Incomplete normalization of ALT Yes 7(0.467) 6(0.400) 2(0.133) 10(0.333) 0.70 1.18 [0.51-2.74]
(at 6 months post diagnosis) No 26(0.419) 26(0.419) 10(0.161) 46(0.371)
rs1800629 (TNF) AA AG GG A
Fibrosis ≥Metavir 3 Yes 5(0.111) 19(0.422) 21(0.467) 29(0.322) 0.68 1.16 [0.57-2.35]
(at diagnosis) No 4(0.129) 10(0.323) 17(0.548) 18(0.290)
Incomplete normalization of ALT Yes 1(0.067) 7(0.467) 7(0.467) 9(0.300) 0.81 0.90 [0.38-2.14]
(at 6 months post diagnosis) No 9(0.145) 22(0.355) 31(0.500) 40(0.323)
rs1800682 (FAS) CC CT TT C
Fibrosis ≥Metavir 3 Yes 14(0.311) 21(0.467) 10(0.222) 49(0.544) 0.035 2.03 [1.05-3.93]
(at diagnosis) No 5(0.161) 13(0.419) 13(0.419) 23(0.371)
Incomplete normalization of ALT Yes 9(0.600) 4(0.267) 2(0.133) 22(0.733) 0.0015± 3.94 [1.62-9.54]
(at 6 months post diagnosis) No 10(0.161) 31(0.500) 21(0.339) 51(0.411)
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found the HLA-DRB1*03:01 allele to be the principle
genetic risk factor for type 1 AIH in these populations.
The HLA-DRB1*04:01 allele has also associated, albeit to
a lesser degree, with the type 1 AIH in European and
North American Caucasians (Czaja 2008). In our cohort,
we did not find an association of HLA-DRB1*04:01 with
overall susceptibility, despite having 100% power to de-
tect an effect size of 5.97 at α=0.05 (Strettell, Donaldson
et al. 1997). We also found that the minor allele of SNP
rs1800629, which tags the extended haplotype HLA-A1-
B8-DR8, was significantly associated with overall disease
risk (p = 0.004, OR = 1.89, 95% CI 1.21-2.94) in New
Zealand Caucasians, consistent with findings of previous
studies (Donaldson et al. 1991, Al-Chalabi et al. 2008).
In addition to the HLA locus, we tested SNPs within
the CTLA4, FAS and TNF genes for association with
type I AIH. TNF is a key cytokine in the inflammatory
response and variations in expression of TNF have been
implicated in many autoimmune diseases. There is
evidence suggesting that the promoter polymorphism
TNF -308G > A (rs1800629) increases expression of
TNF, and an association of this polymorphism with type
1 AIH has been reported in a number of cohorts (Tang
et al. 2012). In our cohort of New Zealand Caucasians,
the minor allele TNF -308A conferred susceptibility to
AIH (OR = 2.06, 95% CI [1.41-3.01], p = 0.0001). In con-
trast to overall susceptibility, we found no evidence of
association of TNF -308G > A with either severe fibrosis
at diagnosis or incomplete normalization of ALT at
6 months.
CLTLA4 codes for a T cell surface molecule that plays
a key role as a negative regulator of T cell responses by
inducing T cell apoptosis on binding to B7 molecules on
antigen-presenting cells. CTLA4 49G/G genotype
changes the sequence of CTLA4 (threonine to alanine)
and leads to diminished inhibitory effects on T cell pro-
liferation, and hence, hyperactivity of T cells (Kouki
et al. 2000). Several studies have examined CTLA4 49A
> G (rs231775) in AIH although nearly all them have
failed to show a definitive association between rs231775
polymorphism and disease susceptibility (Agarwal, Czaja
et al. 2000; Bittencourt et al. 2003; Fan et al. 2004; Schott
et al. 2007; Umemura et al. 2008). Nevertheless, a recent
combined analysis of these studies comprising 526 pa-
tients with type 1 AIH and 631 matched controls
reported the CLTLA4 49A/A genotype conferred protec-
tion against type 1 AIH (OR = 0.66, 95% CI 0.50-0.86)
(Miyake et al. 2011). In our cohort we detected no asso-
ciation of the exon 1 SNP CLTLA4 49A > G (rs231775)
with overall disease susceptibility. However, we did find
an increased risk of severe liver fibrosis at presentation
in patients who were homozygous for minor allele of
rs231775 (OR = 8.57, 95% CI [1.04-70.89], p = 0.046),although this association was not significant after cor-
rection for multiple testing.
FAS is a member of the TNF receptor superfamily of
membrane-bound molecules. In vitro studies have shown
that FAS plays a prominent role in the induction of hep-
atocyte apoptosis and tissue destruction in AIH (Fox et al.
2001). Moreover the promoter polymorphism FAS -670
T > C results in higher expression of FAS on the surface
of activated T cells (Sun et al. 2005) and, although this
polymorphism has not been associated with overall sus-
ceptibility to type 1 AIH, the minor allele FAS -670C was
found to confer protection against early onset cirrhosis in
Caucasian type 1 AIH patients (Agarwal, Czaja et al.
2007). In our study we found that whilst FAS -670A > C
was not associated with overall disease susceptibility in
our New Zealand Caucasian patients, the FAS -670C allele
confers risk of severe fibrosis at diagnosis (OR = 2.03, 95%
CI 1.05-3.93, p = 0.035). In addition, the FAS -670C allele
was significantly associated with failure to achieve
complete normalization of ALT at 6 months post-
diagnosis compared to the FAS -670 T allele (OR = 3.94,
95% CI 1.62-9.54, p = 0.0015). Our earlier study had dem-
onstrated that incomplete normalization of ALT at
6 months is an independent predictor of liver related
death (Ngu, Gearry et al. 2013). These observations sug-
gest that the presence of the FAS -670C allele is associated
with a more aggressive disease phenotype.
Multivariate analysis showed that rs2187668 (HLA-
DRB1*03:01) was the only independent risk allele signifi-
cantly associated with the overall susceptibility to type 1
AIH. This result is of interest as we have shown for the
first time that while HLA-A1-B8-DR3 and TNF were as-
sociated with type 1 AIH susceptibility, they were also
significantly associated with HLA-DRB1*03:01. Our
study demonstrates that, under the multivariate model,
HLA-DRB1*03:01 was the dominant risk allele.
The strength of the present study is its population-
based nature leading to results that are representative of
the spectrum of AIH, as opposed to clinic-based studies
where patients with more severe phenotypes are often
over-represented. The weakness of this study is its small
study size, and therefore it may be underpowered in
confirming weaker associations. Nevertheless, it is im-
portant to note that despite the relatively small sample
size, the results presented in this study did show highly
significant associations.
Conclusions
Our study is the first population-based study to test for as-
sociation of selected genetic loci with type 1 AIH and also
the first study performed in New Zealand Caucasians.
We report significant independent association of HLA-
DRB1*03:01 with overall susceptibility to type 1 AIH. FAS,
whilst not associated with type 1 AIH susceptibility, was
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phenotype. These findings are an important first step in
increasing our understanding of the genetic basis of type
1 AIH, and may help guide the selection of candidates for
future functional studies.
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